Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totaling 802,784 shares, an increase of 41,110.7% from the May 31st total of 1,948 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average trading volume of 182,658 shares, the short-interest ratio is presently 4.4 days.

Provectus Biopharmaceuticals Trading Up 1.5%

Shares of Provectus Biopharmaceuticals stock traded up $0.00 on Thursday, reaching $0.07. 60,818 shares of the stock were exchanged, compared to its average volume of 255,105. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.10. The business has a fifty day moving average price of $0.06 and a two-hundred day moving average price of $0.06.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.